Xeris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Xeris Pharmaceuticals Inc. (XERS) Tops Q3 EPS by 17c, Revenues Beat
November 9, 2020 7:00 AM ESTXeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q3 EPS of ($0.35), $0.17 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $9.4 million versus the consensus estimate of $4.48 million.
The third quarter results showed the tremendous response from the diabetes community to the... More
